An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Phase II Results May Support Accelerated Approval

 
• By Mandy Jackson
  
Brainstorming creative idea
Lilly CEO David Ricks outlined the path to Phase II success for donanemab in Alzheimer's disease • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D